Business Description
Xilio Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US98422T1007
Description
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8.63 | |||||
Equity-to-Asset | 0.37 | |||||
Debt-to-Equity | 0.26 | |||||
Debt-to-EBITDA | -0.13 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -6.99 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -11.9 | |||||
3-Year EPS without NRI Growth Rate | -10.3 | |||||
3-Year FCF Growth Rate | -20.5 | |||||
Future 3-5Y EPS without NRI Growth Rate | 29.37 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 56.38 | |||||
9-Day RSI | 50.62 | |||||
14-Day RSI | 47.95 | |||||
6-1 Month Momentum % | 73.51 | |||||
12-1 Month Momentum % | -64.93 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.02 | |||||
Quick Ratio | 2.02 | |||||
Cash Ratio | 1.94 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | 2 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -2830.04 | |||||
Net Margin % | -2780.27 | |||||
FCF Margin % | -735.89 | |||||
ROE % | -151.77 | |||||
ROA % | -81.18 | |||||
ROIC % | -241.44 | |||||
ROC (Joel Greenblatt) % | -602.16 | |||||
ROCE % | -117.35 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 21.74 | |||||
PB Ratio | 1.17 | |||||
Price-to-Tangible-Book | 1.19 | |||||
EV-to-EBIT | 0.41 | |||||
EV-to-EBITDA | 0.42 | |||||
EV-to-Revenue | -11.49 | |||||
EV-to-FCF | 1.56 | |||||
Price-to-Net-Current-Asset-Value | 1.84 | |||||
Price-to-Net-Cash | 2.15 | |||||
Earnings Yield (Greenblatt) % | 243.9 | |||||
FCF Yield % | -44.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XLO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xilio Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 2.357 | ||
EPS (TTM) ($) | -2.11 | ||
Beta | 0 | ||
Volatility % | 97.97 | ||
14-Day RSI | 47.95 | ||
14-Day ATR ($) | 0.067947 | ||
20-Day SMA ($) | 0.895398 | ||
12-1 Month Momentum % | -64.93 | ||
52-Week Range ($) | 0.49 - 2.94 | ||
Shares Outstanding (Mil) | 43.95 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Xilio Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Xilio Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Xilio Therapeutics Inc Frequently Asked Questions
What is Xilio Therapeutics Inc(XLO)'s stock price today?
The current price of XLO is $0.90. The 52 week high of XLO is $2.94 and 52 week low is $0.49.
When is next earnings date of Xilio Therapeutics Inc(XLO)?
The next earnings date of Xilio Therapeutics Inc(XLO) is 2024-11-06 Est..
Does Xilio Therapeutics Inc(XLO) pay dividends? If so, how much?
Xilio Therapeutics Inc(XLO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |